Follow
Shu Ichimiya
Shu Ichimiya
Columbia University, Irving Cancer Research Center
Verified email at cumc.columbia.edu
Title
Cited by
Cited by
Year
RBPJ and MAML3: potential therapeutic targets for small cell lung cancer
H Onishi, S Ichimiya, K Yanai, M Umebayashi, K Nakamura, A Yamasaki, ...
Anticancer research 38 (8), 4543-4547, 2018
182018
Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy
Y Oyama, H Onishi, S Koga, M Murahashi, S Ichimiya, K Nakayama, ...
Journal of Immunotherapy 43 (4), 121-133, 2020
172020
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor
A Fujimura, K Nakayama, A Imaizumi, M Kawamoto, Y Oyama, S Ichimiya, ...
Cancer Immunology, Immunotherapy 68 (10), 1649-1660, 2019
172019
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor
S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ...
Translational oncology 14 (9), 101152, 2021
152021
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer
S Ichimiya, H Onishi, S Nagao, S Koga, K Sakihama, K Nakayama, ...
Oncology reports 45 (3), 997-1010, 2021
142021
Liprin-α4 as a new therapeutic target for sclc as an upstream mediator of hif1α
H Onishi, A Yamasaki, K Nakamura, S Ichimiya, K Yanai, M Umebayashi, ...
Anticancer research 39 (3), 1179-1184, 2019
142019
FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients
K Saeki, H Onishi, S Koga, S Ichimiya, K Nakayama, Y Oyama, ...
Journal of Cancer 11 (8), 2289, 2020
112020
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with …
S Ichimiya, A Fujimura, M Masuda, S Masuda, R Yasumatsu, ...
Immunological Investigations, 1-17, 2021
82021
C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions
S Nagao, H Onishi, M Kawamoto, S Masuda, L Na, S Morisaki, N Iwamoto, ...
Journal of Cancer 14 (2), 306-317, 2023
42023
NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes
K Nakayama, H Onishi, A Fujimura, A Imaizumi, M Kawamoto, Y Oyama, ...
Cellular Immunology 358, 104237, 2020
42020
Prediction of negative outcomes in non-surgical treatment for appendiceal abscess in adults
Y Sadakari, S Date, S Murakami, S Ichimiya, S Nishimura, H Kawaji, ...
Journal of the Anus, Rectum and Colon 2 (2), 59-65, 2018
32018
Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice
K Saeki, W Qiu, RA Friedman, S Pan, J Lu, S Ichimiya, IIC Chio, ...
Cancer Research Communications, 2022
22022
Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor …
S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ...
Translational Oncology 17, 2022
12022
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor (vol 14, pg …
S Koga, H Onishi, S Masuda, A Fujimura, S Ichimiya, K Nakayama, ...
TRANSLATIONAL ONCOLOGY 17, 2022
2022
GLI2/Hedgehog Signaling Contributes to the Induction of Malignant Phenotype of Gallbladder Cancer
S Ichimiya, H Onishi, S Matsushita, S Koga, Y Fujioka, K Nakayama, ...
HPB 23, S347-S348, 2021
2021
Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer
A Yamasaki, S Koga, S Ichimiya, K Nakayama, Y Oyama, Y Fujioka, ...
Annals of Oncology 30, v808, 2019
2019
Maml3 Contributes to the Induction of Malignant Phenotype for Gallbladder Cancer Via the Morphogenesis Signaling Under Hypoxia
L Na, H Onishi, S Ichimiya, Y Yamada, S Masuda, S Nagao, S Koga, ...
Available at SSRN 4220679, 0
The system can't perform the operation now. Try again later.
Articles 1–17